NSE: GLAXO | BSE: 500660

Falling Comet

Download real time

2464.30 -22.60 (-0.91%)

29.91% Fall from 52W High

34,009 NSE+BSE Volume

NSE 26 Dec, 2025 3:31 PM (IST)

41,746.7

Market Cap

High in industry

Beta 1Year

Low volatility

GlaxoSmithKline Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GLAXO, BSE:500660 GlaxoSmithKline Pharmaceuticals Ltd.

GlaxoSmithKline Pharmaceuticals Ltd.

07 Feb 2021

2464.30

-0.91%

Better operating leverage drives profitability

Neutral: GlaxoSmithKline Pharmaceut...

Target

Motilal Oswal

GSK Pharma (GLXO)'s 3QFY21 performance was better than estimated, with an increase in sales driving higher profitability (on account of operating leverage). With the intensity of YoY decline lower over the past two quarters, GLXO exhibited low-double-digit YoY growth with the easing of the lockdown and partly aided by the low base of the past year. We increase our EPS estimates by 8%/3%/2% for FY21/FY22/FY23E, factoring in strong recovery in key therapies and improving productivity. We continue to value GLXO at 38x 12M forward earnings (25% discount to its...

Number of FII/FPI investors decreased from 390 to 362 in Sep 2025 qtr

GlaxoSmithKline Pharmaceuticals Ltd.

31 Jul 2020

2464.30

-0.91%

GlaxoSmithKline Pharmaceuticals Ltd

Sell: GlaxoSmithKline Pharmaceut...

Target

Karvy

Outlook & Valuation: We downgrade our revenue estimates for FY21E / FY22E by 4.6% / 4.6% to Rs. 32.9 Bn / Rs. 36.3 Bn for FY21E / FY22E. We downgrade our EBITDA margins for FY21E / FY22E by 50 bps to 20.6%/21.9% due to fixed nature of personal cost.

GlaxoSmithKline Phar.. has an average target of 2750.00 from 2 brokers.

GlaxoSmithKline Pharmaceuticals Ltd.

29 Jul 2020

2464.30

-0.91%

COVID-19-led weakness in performance

Neutral: GlaxoSmithKline Pharmaceut...

Target

Motilal Oswal

29 July 2020 GSK Pharma (GLXO)s performance for the quarter was deeply impacted by the COVID-19-led disruption. As a result, the company posted the lowest revenue recorded in the past 16 quarters. The severity amplified with reduced operating leverage. The outlook is expected to gradually improve with the easing of the lockdown. We reduce our EPS estimate by 26.3%/11.7% for FY21/FY22 to factor COVID- 19-led weakness in the Prescription and Vaccination segments. We continue to value GLXO at 37x 12M forward earnings (25% discount to its three-year average) to arrive at TP of INR1,355. GSK Pharma revenues were down 17.7% to INR6.5b (v/s est. GM expanded 230bp YoY to 60.

GlaxoSmithKline has lost -25.37% in the last 6 Months

GlaxoSmithKline Pharmaceuticals Ltd.

19 May 2020

2464.30

-0.91%

GlaxoSmithKline Pharmaceuticals Ltd-Results Update

Sell: GlaxoSmithKline Pharmaceut...

Target

Karvy

GlaxoSmithKline Pharmaceuticals Ltd: Outlook & Valuation: We downgrade our revenue estimates for FY21E by 4.3% to Rs 34.5 bn and introduce our revenues for FY22E.

Number of FII/FPI investors decreased from 390 to 362 in Sep 2025 qtr

GlaxoSmithKline Pharmaceuticals Ltd.

04 Feb 2020

2464.30

-0.91%

Loss of Zinetac sales leads weak earnings

Neutral: GlaxoSmithKline Pharmaceut...

Target

Motilal Oswal

4 February 2020 GSK Pharma (GLXO) was able to improve profitability over FY17-9MFY20, led by product rationalization/enhanced focus on high-margin products. However, its decision to stop selling Zinetac brand (~6% of sales) should have an adverse impact on near-term growth. We expect 8-9% sales CAGR over the next 2 years after adjusting for the loss of Zinetac sales. We reduce our EPS estimates by 12.8%/1.7%/1.3% and reduce P/E multiple to 41x (from 43x earlier) to factor in the (a) voluntary stoppage of Zinetac, and (b) gradual industry-wide slowdown in the anti-infective category with improved hygienic conditions/lower intensity of epidemics. Revenue declined 6% YoY to INR7.8b (v/s est. Adj. for the voluntary recall of ranitidine products and portfolio-optimization initiative, revenue was up 6% YoY. Gross margin (GM) expanded 430bp YoY (+20bp QoQ) to 57.9%, led by the change in product mix.

Number of FII/FPI investors decreased from 390 to 362 in Sep 2025 qtr

GlaxoSmithKline Pharmaceuticals Ltd.

23 Oct 2019

2464.30

-0.91%

GSK Pharma: RESULT REVIEW

Sell: GlaxoSmithKline Pharmaceut...

Target

Karvy

Revenue growth lower than estimates: Revenues for the quarter at Rs 8821 mn were below our estimates of Rs 9469mn on account of lower traction.

GlaxoSmithKline Phar.. has an average target of 2750.00 from 2 brokers.

GlaxoSmithKline Pharmaceuticals Ltd.

22 Oct 2019

2464.30

-0.91%

Superior product mix/better operating leverage drives profitability

Neutral: GlaxoSmithKline Pharmaceut...

Target

Motilal Oswal

22 October 2019 2QFY20 sales increased 8% YoY to INR8.8b (v/s est. Gross margin (GM) stood at 58.1% and improved 80bp YoY (stable QoQ) due to portfolio rationalization. EBITDA margin improved ~175bp YoY to 22% on account of the superior product mix and lower other expenses as % of sales (-60bp YoY to 18.2%). Employee cost was also down, 40bp YoY, supporting margin expansion. As a result, EBITDA increased ~17.5% YoY to INR1.9b (v/s est. Adj PAT came in at INR1.

GlaxoSmithKline Pharmaceuticals Ltd. is trading below all available SMAs

GlaxoSmithKline Pharmaceuticals Ltd.

05 Aug 2019

2464.30

-0.91%

GlaxoSmith Con

Hold: GlaxoSmithKline Pharmaceut...

Sharekhan

steady operating performance with revenue growing by ~8% (driven by 5.4% volume growth). Strong expansion in EBIDTA margins and higher other income led to strong bottom-line growth. Horlicks continued to maintain its leadership in the Health Food Drinks (HFD) category with 44% market share. Premium products gaining good traction coupled with new product launches and improving penetration will be key revenue drivers going ahead. The integration of GSK Consumer and Hindustan Unilever (HUL) will take place by...

Number of FII/FPI investors decreased from 390 to 362 in Sep 2025 qtr

GlaxoSmithKline Pharmaceuticals Ltd.

23 Jul 2019

2464.30

-0.91%

GSK Pharma: Slower revenue growth.

Sell: GlaxoSmithKline Pharmaceut...

Target

Karvy

Revenues for the quarter at Rs 7880 mn were below our estimates of Rs 8195 mn. The operating margins at 21% in Q1FY20 were below our estimates of 23.2% on account of lower revenue traction and lower gross margin.

GlaxoSmithKline has lost -25.37% in the last 6 Months

GlaxoSmithKline Pharmaceuticals Ltd.

13 May 2019

2464.30

-0.91%

GlaxoSmith Con

Hold: GlaxoSmithKline Pharmaceut...

Sharekhan

Volume growth sustains; Low input cost and efficiencies led to margin expansion: GSK Consumer reported strong results in Q4FY2019, with broad-based growth across products and channels. Revenue grew by 9%, driven by 6.3% volume growth. Business auxiliary income rose by 20% y-o-y, led by double-digit growth across all products. Unlike other FMCG companies, GSK...

GlaxoSmithKline has lost -25.37% in the last 6 Months

Is GlaxoSmithKline Pharmaceuticals Ltd. worth buying?

125 Votes:

Buy 66.4%

Sell 20.8%

Hold 12.8%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Neutral SEE REPORTS >

pdf